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Background: Elevated maternal triglycerides have been associated with adverse pregnancy outcomes including an
increased risk of preeclampsia and macrosomia. A valid triglyceride meter would allow the examination of maternal
postprandial triglycerides in a systematic manner. A non-fasting venous and two capillary measurements (using the
Roche Accutrend® Plus meter) of triglycerides were measured in 40 participants at a mean of 36 weeks gestation.
Findings: The two methods were highly correlated (r = 0.89, P <0.0001), and the distributions were similar (mean
difference 0.01 mmol/L (SD 0.47)), t = 0.18, P =0.86). Passing Bablok equation was: y = −0.01 + 0.98 × [95% CI
intercept −0.51 – 0. 38; 95% CI slope 0.85-1.15). The estimated bias was −0.01 mmol/L (95% CI −0.93 – 0.91)).
Conclusions: This study demonstrated the Accutrend® Plus meter provides results that correlate strongly with the
reference method, with low bias, when used in late pregnancy.
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In pregnancies complicated by diabetes mellitus as well as
in non-diabetic pregnancy, elevated maternal triglycerides
are associated with adverse pregnancy outcomes including
an increased risk of preeclampsia [1], and macrosomia
[2-4]. Most studies have examined fasting maternal tri-
glycerides, or random triglycerides either at a single time
point or at isolated times across pregnancy. In compari-
son, regular home based measurement of postprandial
glucose is a cornerstone of the management of diabetes
during pregnancy. Elevated postprandial triglycerides are
associated with adverse outcomes in the non-pregnant
population [5] but this has not been systematically studied
in pregnancy. Examination of the role of maternal post-
prandial triglycerides in pregnancy outcomes has been
hampered by the lack of an appropriately accurate, prac-
tical and validated method.
In late pregnancy, maternal metabolism undergoes mul-
tiple alterations including increased triglyceride present in
very low density lipoprotein, high density lipoprotein and* Correspondence: h.barrett@uq.edu.au
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unless otherwise stated.low density lipoprotein [6,7]. The alterations in lipoprotein
composition during late pregnancy could affect the per-
formance of point of care assays. The purpose of this
study was to validate the Roche Accutrend® Plus system
using triglyceride strips, in pregnancy.
Methods
40 women were enrolled in late pregnancy. Gestational
diabetes mellitus (GDM) was diagnosed according to the
Australasian Diabetes in Pregnancy Society criteria [8].
Random morning venous serum triglycerides (Beckman
DXC800) were performed, with simultaneous dual meas-
urement of capillary triglycerides using the Accutrend®
Plus system (Roche Diagnostics, Mannheim, Germany).
The Beckman DXC800 measures triglycerides by cleav-
age of the triglycerides into glycerol and free fatty acids,
then further enzymatic steps producing a dye, and this
dye product is measured by change in absorbance at 520
nanometers. Our clinical laboratory is a commercial
laboratory, National Association of Testing Authorities,
Australia (NATA) accredited to ISO 15189 standard.
The Accutrend® Plus test works by cleavage of the tri-
glycerides into glycerol and free fatty acid, with further
enzymatic steps producing hydrogen peroxide, the con-
centration of which is measured by reflectance photom-
etry. The Accutrend® Plus manufacturer reports withinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Barrett et al. BMC Research Notes 2014, 7:679 Page 2 of 4
http://www.biomedcentral.com/1756-0500/7/679series imprecision CV of up to 3.4% (in the pathological
range) and day to day imprecision CV 2.3% and meas-
urement range of 0.80 – 6.86 mmol/L. The capillary tri-
glycerides were measured using the same meter for each
woman, but with variable meters used between women.
The venous sample was transported on ice to the labora-
tory and the triglycerides measured in the general clin-
ical laboratory run on the day of sampling.
Normality of data was assessed using Shapiro-Wilk
tests. The accuracy of the Accutrend® Plus was determined
by comparing the results of the simultaneously sampled
venous plasma and the first of the two capillary results
measured, using paired sample t-tests and Pearson’s cor-
relation coefficients. Data is presented as mean and stand-
ard deviation unless otherwise noted. The agreement
between capillary and reference method was assessed
using Passing Bablok regression [9] and Bland-Altman
analysis [10]. These analyses were also performed for the
mean of the capillary measurements compared with the
reference method and the results were similar (not
shown). Sensitivity analyses were performed excluding
the six women with normal glucose tolerance and this
did not alter the results. Statistical analyses were per-
formed using MedCalc Statistical Software version 14.8.1
(MedCalc Software bvba, Ostend, Belgium; http://www.
medcalc.org; 2014).
Permission for the study was granted by The Royal
Brisbane and Women’s Hospital Human Research Ethics
Committee and The University of Queensland Human
Research Ethics Committee. All women gave written in-
formed consent. The study was funded by the Research
Advisory Committee, The Royal Brisbane and Women’ s
Hospital.Findings
Venous and concomitant capillary samples were collected
from 40 women at an average gestational age of 253 (SD
5) days. Thirty-four of the 40 subjects had been diagnosedFigure 1 Graphs of comparison between methods. A. Passing Bablok re
Accutrend® Plus. B. Bland Altman Plot for the difference between methodsand were being treated for gestational diabetes mellitus;
the remaining 6 had normal glucose tolerance. Three of
the women with gestational diabetes mellitus were being
managed with insulin therapy, two with metformin and
one with both insulin and metformin. Maternal character-
istics were as follows: mean age 31.0 (SD 9.9) years, mean
gestation of delivery 253 (SD 5) days, recalled pre-
pregnancy body mass index (BMI) 26.7 (SD 6.3) kg/m2
mean HbA1c for the women with gestational diabetes
mellitus 5.44% (SD 0.47) (36 mmol/mol (SD 5.1)), mean
HbA1c for normoglycaemic women 5.22% (SD 0.16)
(34 mmol/mol (SD 1.7)), mean hematocrit 0.38% (SD
0.03) and mean serum creatinine 48.4 μmol/L (SD 7.8).
The mean maternal serum triglyceride was 3.21 mmol/L
(SD 0.97). The reference method was highly correlated
with the capillary method (r = 0.89, P <0.0001), and the
two distributions were not statistically different (mean
difference 0.01 mmol/L (SD 0.47), t = 0.18, P =0.86).
Passing Bablok regression equation was: y = − 0.01 +
0.98 × (95% CI for the intercept −0.51 – 0.38; 95% CI
for the slope 0.85 – 1.15) (Figure 1A). The estimated bias
was −0.01 mmol/L (−0.5%) (95% CI −0.93 – 0.91 mmol/L
(−28.5% - 27.5%)) (Figure 1B). The 95% CI of the bias was
broad. There was no significant difference between the two
capillary triglyceride measurements (3.23 mmol/L (SD
1.01); 3.13 mmol/L (SD1.02): mean difference −0.09 mmol/L
(SD 0.71) t = −0.81; P = 0.42)).Discussion
This is the first study to examine the measurement of
maternal triglycerides in late pregnancy using the Roche
Accutrend® Plus. The Accutrend® Plus has previously
been examined in two studies in the non-pregnant
population. Both studies reported acceptable agreement
between methods [11,12]. The mean bias found in the
current study (−0.01 mmol/L (−0.5%)) was smaller than
that found in either of the previous two studies using
the Accutrend® Plus (8.8% [11]; 0.26 mmol/L [12]).gression plot for triglycerides determined on laboratory method and
.
Barrett et al. BMC Research Notes 2014, 7:679 Page 3 of 4
http://www.biomedcentral.com/1756-0500/7/679While the mean bias measured in the current study was
low, the 95% confidence intervals of the bias was broad
but not dis-similar to those found in previous studies of
this meter [11,12]. This may be contributed to by person
to person variability in the difference between methods
or by the formal venous triglycerides being measured in
the clinical run rather than in a single batch. Performing
the formal triglycerides in the clinical run may have
introduced more error than otherwise would have been
found but is more reflective of a potential “real use”
situation.
A concern raised by Scafoglieri [12] was that the
Accutrend® Plus should not be used for diagnosis of
hypertriglyceridemia. Given this, in addition to method
comparison, it would be useful to undertake practicabil-
ity analyses. These have yet to be performed for the
Accutrend® Plus in pregnancy. In the current study, the
correlation between the two capillary measures taken by
study staff was high.
It needs to be borne in mind that the purpose of
measuring triglyceride levels in the pregnancy setting is
not for the diagnosis of maternal hypertriglyceridemia
but to potentially allow assessment of the variation in
triglycerides throughout the day. This would provide
for a detailed assessment of the association of postpran-
dial triglycerides with pregnancy outcomes. Further, the
triglyceride meter could be utilized for self-monitoring
of postprandial triglycerides as glucose meters are cur-
rently used in diabetes in pregnancy, providing feedback
on the effects of food choices. Given we have demon-
strated that this meter has low bias, it would be possible
to use this device in the research setting to examine ma-
ternal triglycerides in pregnancy. In the non-pregnancy
setting, the Accutrend® GCT meter has been used for
home monitoring [13,14] and was found to be useful.
The primary limitation of the current study is that it
has not assessed the ease of use of the meter. In com-
parison to glucose meters which have been specifically
designed for use by the non-clinician, the Accutrend®
Plus meter has been designed more as a point of care
meter for use in clinical settings. Prior to using the
meter on a broader scale, the practicality and reliability
of the non-clinician using the meter at home need to be
assessed.
Conclusions
The Accutrend® Plus meter offers a measurement of
maternal triglycerides that has low bias when compared
with the reference method. While the 95% confidence
intervals around the bias are broad, the use of this
device in clinical studies of pregnancy, outside a diag-
nostic setting would seem reasonable. The practicality
of use of the meter in the pregnancy setting requires
further investigation.Competing interests
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